Related Experiment Video

Updated: Jan 30, 2026

Generation of Monoclonal Antibodies Against Natural Products
12:15

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

11.6K

Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies

Xue Han1, Matthew D Vesely2

  • 1Department of Immunobiology, Yale School of Medicine, New Haven, CT, United States.

International Review of Cell and Molecular Biology
|January 13, 2019
PubMed

Insights

Immunotherapies harnessing antitumor immunity are advancing cancer treatment. This review covers next-generation immunostimulatory antibodies targeting T-cell costimulatory receptors like CD137 and OX40 for enhanced cancer elimination.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Antitumor immunity for cancer cell elimination has been a long-standing goal since the 1950s.
  • Cancer immunotherapies, particularly monoclonal antibodies (mAbs), are increasingly effective against established cancers.
  • Current mAbs target inhibitory T-cell receptors (CTLA-4, PD-1); next-generation mAbs aim to stimulate T cells.

Purpose of the Study:

  • To review recent advancements in immunostimulatory agonist antibodies.
  • To focus on antibodies targeting T-cell costimulatory receptors.

Main Methods:

  • Literature review of recent progress in cancer immunotherapy.
  • Focus on monoclonal antibodies (mAbs) targeting specific costimulatory receptors.

Main Results:

  • Significant progress has been made in developing immunostimulatory agonist antibodies.
  • These antibodies target key costimulatory receptors including CD137, GITR, OX40, and CD27.
  • This approach represents a promising next generation of cancer immunotherapy.

Conclusions:

  • Immunostimulatory agonist antibodies targeting costimulatory T-cell receptors are a rapidly advancing area of cancer immunotherapy.
  • These therapies hold potential for enhancing antitumor immunity and improving cancer treatment outcomes.
Keywords:
AgonistCancer immunotherapyImmunooncologyImmunostimulatory

More Related Videos

Generation of Murine Monoclonal Antibodies by Hybridoma Technology09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

43.7K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

19.3K

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
954
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.5K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.6K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K